35 studies found for:    " January 21, 2009":" February 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
22 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
23 Completed TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
Conditions: Tuberculosis;   HIV
Intervention: Drug: TMC207
24 Completed VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer
Conditions: Hepatitis C;   HCV;   HIV;   AIDS
Intervention: Drug: Efavirenz; Tenofovir disoproxil fumarate; Telaprevir
25 Completed TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.
Conditions: HIV;   Pharmacokinetics
Intervention: Drug: TMC125
26 Completed
Has Results
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Other: Placebo;   Biological: TUTI-16 (0.03mg);   Biological: TUTI-16 (0.1mg);   Biological: TUTI-16 (0.6mg)
27 Unknown  Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa
Conditions: Cryptococcal Meningitis;   HIV Infections
Interventions: Drug: Fluconazole;   Drug: Fixed dose - Stavudine, lamivudine and Nevirapine;   Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine
28 Unknown  An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
Conditions: Using Cocaine or Heroin in the Last 7 Days,;   Age Over 18 Years Old,;   Competent to Sign Informed Consent for HIV/HBV/HCV Testing,;   HIV/HBV Negatives Will be Randomized for HB Vaccine Study;   HIV Infections
Interventions: Biological: hepatitis B vaccine schedule;   Behavioral: HBV Vaccination Self-Efficacy Intervention
29 Unknown  Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
Conditions: HIV;   Hyperlipidemia;   HIV Infections
Interventions: Drug: ezetimibe;   Drug: fenofibrate;   Drug: pravastatin
30 Completed A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
Conditions: HIV;   HIV Infections
Intervention:
31 Completed PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Condition: HIV-1
Intervention: Drug: TMC558445; TMC310911; Darunavir; Placebo
32 Completed Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.
Conditions: HIV-1 Infection;   HIV Infections
Intervention: Drug: darunavir
33 Completed
Has Results
Exercise, Oxidative Stress and HIV
Condition: HIV Infections
Intervention:
34 Completed
Has Results
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
Condition: HIV-1 Infections
Interventions: Drug: Raltegravir;   Drug: Darunavir/Ritonavir
35 Completed
Has Results
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
Condition: Infections, Streptococcal
Interventions: Biological: Pneumococcal vaccine GSK1024850A;   Biological: Tritanrix-HepB/Hib;   Biological: measles;   Biological: Rotarix;   Biological: Local OPV

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-35) Next Page   
Indicates status has not been verified in more than two years